ProQR Therapeutics N.V. (NASDAQ:PRQR) does about 2.90M shares in volume on a normal day but saw 3004307 shares change hands in Monday trading. The company now has a market cap of 183.81M USD. Its current market price is $2.63, marking a decrease of -6.41% compared to the previous close of $2.81. The 52 week high reached by this stock is $6.15 whilst the lowest price level in 52 weeks is $0.53. The script in recent trading has seen the stock touch a high of $2.83 and a low of $2.50.
ProQR Therapeutics N.V. (PRQR) has a 20-day trading average at $3.23 and the current price is -57.24% off the 52-week high compared with 396.23% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.09 and its 200-day simple moving average is $1.12. If we look at the stock’s price movements over the week, volatility stands at 14.80%, which decreases to 13.48% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.54 to suggest the stock is neutral.
8 analysts observing the ProQR Therapeutics N.V. (PRQR) stock have set the 12-month price targets for the company’s shares at between $0.94 and $5.00. The consensus objective for the share price is $3.21, suggesting that the stock has a potential upside of 18.07% over the period. The median price target is 29.87% away from the current levels at $3.75.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 3 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 22, 2022 when Cantor Fitzgerald upgraded the stock to “Overweight” and issued a price target of between $0.80 and $5. Citigroup downgraded the stock to “Neutral” from Buy on February 14, 2022 at a price target of $37-$1.70. Stifel downgraded its price target at $20-$3.
The current price level is -17.44%, 28.12%, and 137.42% away from its SMA20, SMA50, and SMA200 respectively, with the PRQR price moving below the 50-day SMA on January 23. ProQR Therapeutics N.V. (PRQR) stock is down -23.32% over the week and 62.35% over the past month. Its price is -28.92% year-to-date and -52.36% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.36 below consensus estimates by -$0.14. The company’s next earnings report is expected on 05/10/2023, with forecasts estimating quarterly EPS at -$0.18 and -$1 for whole year. PRQR’s earnings per share are forecast to shrink by -2.00% this year and 55.00% over next year. Expected sales for next quarter are $2.38 million, which analysts say will come at $4.61 million for the current fiscal year and next year at $21.94 million. In addition, estimates put the company’s current quarterly revenue at an average of $1.03 million.
Its 12-month price target is $3.75. To reach the target analysts have set, the stock logically needs to grow 18.07 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $0.94, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.00.
Outstanding shares total 71.38M with insiders holding 20.89% of the shares and institutional holders owning 41.47% of the company’s common stock. The company has a return on investment of -32.90% and return on equity of -78.40%. The beta has a value of 0.19. Price to book ratio is 2.68 and price to sales ratio is 42.75.
According to a U.S. Securities and Exchange Commission filing, Aescap Life Sciences has added its position in ProQR Therapeutics N.V. (PRQR) to 4,765,659 shares, mirroring a recent increase by 51.41%. Aescap Life Sciences added 1.62 million shares of ProQR Therapeutics N.V. common stock bringing its total worth to about $17.63 million at the end of recent close, SEC documents show. Aescap Life Sciences isn’t the only investment manager who changed stakes and is followed by JPMorgan Funds – Thematics – Gene, which added 0.26 million shares to end up with 961,511 shares worth $3.56 million.